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COPD patients yields significant costs savings and has a beneficial effect on 
evaluated quality of life.
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Objectives: To estimate health care costs for asthma patients with and without 
a COPD diagnosis. MethOds: Asthma patients with and without diagnosed COPD 
were selected from the HealthCore Integrated Research Database covering admin-
istrative claims from approximately 27.6 million people in the USA. The index 
event was a patient’s first exacerbation defined as oral corticosteroid prescription 
fills or emergency department visits or inpatient visits with a primary diagnosis 
of asthma. Eligibility criteria were ≥ 1 asthma diagnosis, ≥ 1 exacerbation and 12 
months of continuous health plan enrolment on each side of the index date. Total 
all-cause and asthma-related direct health care costs for 12 months before and 
after the index date were calculated for all patients and those with and without a 
COPD diagnosis. Results: A total of 94,883 patients met all eligibility criteria, of 
these 15,127 (15.9%) had both asthma and COPD diagnoses. The mean patient age 
was 41.6 years and 62.4% were female. Co-morbid conditions were more common 
among asthma patients with a COPD diagnosis. Asthma-related direct costs repre-
sented 25-30% of all-cause direct health care costs for all patients. Among asthma 
patients, COPD and its associated co-morbidities roughly doubled all-cause and 
asthma related direct health care costs: mean annual pre-index all-cause health 
care costs were $20,012 (COPD diagnosis) versus $8,938 (no COPD diagnosis); mean 
annual pre-index asthma related costs were $5,623 (COPD diagnosis) versus $2,600 
(no COPD diagnosis). Mean annual post-index costs were almost unchanged: all-
cause costs of $21,692 (COPD diagnosis) versus $10,787 (no COPD diagnosis) and 
asthma-related costs of $5,242 (COPD diagnosis) versus $3,016 (no COPD diag-
nosis). cOnclusiOns: The economic burden of asthma among patients with a 
COPD diagnosis in a US claims database is twice as high as those without a COPD 
diagnosis. Further research could adjust for the effects of age on the prevalence 
of co-morbidities among the different groups.
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Objectives: Smoking has a tremendous impact on public health and has been a 
cause of major concern in Greece for more than twenty years. In times of economic 
recession when household income drops and health spending is decreasing, the 
demand for health services is transferred to the public sector. In light of the above, 
the aim of this study was to measure the number of smoking-related hospitaliza-
tions and the additional hospital costs for the treatment of smoking-attributable 
diseases. MethOds: A prevalence-based disease specific approach was used for the 
calculations. Greek-specific smoking-attributable fractions (SAFs) were calculated 
for all smoking-related diseases, coded according to the International Classification 
of Diseases ICD-10. Smoking attributable morbidity was obtained by applying the 
SAFs to all public hospital admissions for 2011. Total hospital costs associated with 
smoking were calculated by applying the smoking-attributable admissions to each 
DRG rate. Results: For Greece, lung cancer (C33-C34), bronchitis and emphysema 
(J40-J42, J43) presented the highest disease-specific SAF with a value of 88.4% and 
88.1% respectively. In 2011, smoking was responsible for 199,028 hospital admis-
sions (8.9 % of total). Smoking-attributable hospital costs, based on the current 
pricing DRG system, has reached 400,011,801€ representing 7.7% of public hospital 
budgets. Ischemic heart disease (I20-I25) was found to be the main cost driver (90.3 
million € ), followed by other circulatory diseases (I00-I09, I26-I51) (55.8 million€ ) and 
pneumonia, influenza (J10-J18) (52.6 million € ). cOnclusiOns: Despite evidence 
of a decreasing trend, smoking is still a considerable public health issue in Greece 
and has a great impact on public health care system. Vigorous efforts have been 
implemented to promote a smoke-free environment and to enforce existing anti-
smoking legislation however the Greek society still experiences a high proportion 
of smoking-attributable admissions and hospital treatment costs. The findings of 
this study further corroborate a call for stronger support of cost-effective tobacco 
control policies.
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Objectives: Surveys have found high rates of pain medication use among COPD 
patients. However, few data exist on how chronic pain affects health care utilization. 
We examined how chronic pain affects direct medical costs in COPD and a matched 
cohort of patients with other chronic diseases. MethOds: We conducted a retro-
spective analysis using claims data from one managed care system. COPD patients 
were matched by age, sex, insurance type, and encounter type to persons with 
other chronic conditions but without COPD [Alzheimer’s, atrial fibrillation, cancer, 
kidney disease, acute myocardial infarction, diabetes, heart failure, ischemic heart 
disease, rheumatoid/osteoarthritis (RA/OA), and stroke]. Chronic pain was indicated 
by pain-associated diagnoses, procedures for pain interventions, or prescription 
fills for pain medications. Results: The study cohort (7,952 COPD patients, 15,904 
non-COPD) was 58% female; mean age, 69. A higher percentage of COPD patients 
were chronic users of any pain medication (41.2% vs 31.5%, P< 0.0001). The only 
patients’ treatment adherence and persistence. MethOds: A systematic review 
of the literature was performed in MedLine/PubMed, Cochrane Library, ISI WOK, 
MEDES, IBECS, CSIC, Google Scholar (2002-2012) to identify articles referred to 
direct COPD cost and treatment persistence and adherence. Based on the direct 
cost data extracted, the annual cost difference between an adherent and non-
adherent and a persistent and non-persistent patient in Spain was estimated. 
Costs were updated to € , 2012. Results: A total of 48 articles were included (9 
Spanish; 39 international). The mean annual direct cost of a COPD patient in Spain 
varies between € 301 and € 4.226, depending on the publication. Patients’ adherence 
and persistence on COPD treatment and their annual costs was analyzed in 3 arti-
cles (no Spanish publications identified). Multiple inhaled treatments and devices 
of complex use contribute to poor adherence and persistence and to higher medi-
cal resources use and more exacerbations. Treatment adherence and persistence 
implies a 9% and 3% decrease in mean annual direct cost of a COPD patient, respec-
tively, while non-adherence and non-persistence means an increase of 5% and 
13%. The difference between the mean annual direct cost associated to adherent 
and to non-adherent patient varies from € 43 to € 601 (depending on the selected 
publication) and rises up to € 89 to € 1.674 in severe COPD patients. A difference 
between annual direct cost in persistent and non-persistent patient was estimated 
in € 47 to € 666 that reached € 99 to € 1.855 in severe COPD patients. cOnclusiOns: 
Treatment adherence and persistence information is scarce. Therapeutic strategies 
improving patient adherence and persistence may optimize outcomes contribute 
to COPD costs contain.
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Objectives: The Casemix databases contain clinical costing information from hos-
pitals in Malaysia, Indonesia and the Philippines. The objective of this study was to 
determine burden of pneumonia in these three countries. MethOds: Pneumonia 
cases occurring in a single year were identified using ICD10 codes, J10-J18. Patients 
were further categorized into community-acquired pneumonia (CAP) or hospital-
acquired pneumonia (HAP); CAP if they had 1) a primary diagnosis of pneumonia, 
or 2) secondary diagnosis of pneumonia with primary diagnosis of a respiratory 
condition; HAP cases had pneumonia in any of the secondary diagnosis fields with 
non-respiratory primary diagnoses. Descriptive analysis was performed to ascertain 
patient age groups, mean age, mean length of stay (LOS) and case fatality rates 
(CFR). Results: A total of 15,851 pneumonia cases in year 2010 for Indonesia and 
Philippines and 2011, for Malaysia were included in the analysis. The mean age 
of patients was 47.5 years in Malaysia, 36.6 years in Indonesia and 23.5 years in 
Philippines. There was a preponderance of CAP cases among the very young and 
the very old while HAP cases were more likely to occur in older persons. The overall 
CFR of all pneumonia hospitalizations was 11.5% for Malaysia, 5.2% for Indonesia 
and 3.6% for Philippines. The cost of hospitalization was USD 1,177.50, USD 1,103.80 
and USD 254.30 in Malaysia, Indonesia and Philippines respectively. The mean LOS 
in days was 9.2, 8.0 and 6.6 in the three countries, respectively. cOnclusiOns: 
Our study is the first to utilize these databases to study and compare the burden of 
pneumonia across three countries in Asia. The CFR and LOS varied in each of the 
countries likely due to a variety of reasons including differences in socio-economic 
conditions, patterns of infection as well as health system differences. In conclu-
sion, pneumonia is significant burden in the South East Asian countries studied.
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Objectives: To evaluate cost and cost-effectiveness of tiotropium monotherapy 
administered for 24 months (18 mcg die) in patients suffering from mild-to-
moderate and severe chronic obstructive pulmonary disease (COPD). MethOds: 
A recent published study showed that tiotropium monotherapy enables a sig-
nificant minimization of morbidity in two groups of patients corresponding to 
predicted FEV1 baseline values ≤ 50% (A) and > 50% (B). Clinical outcomes (days 
in hospital, visits in general ward, cycles of systemic steroids, cycles of antibiotics 
and maintenance therapy drugs) were evaluated from the Italian NHS perspective. 
In order to perform cost-effectiveness analysis, FEV1 value, available for each 
patient, was converted in SGRQ score using a published multivariate linear model; 
then utilities were obtained through the Ståhl equation. Results: Results from 
comparison between 24 months of standard therapy and subsequent 24 months 
of tiotropium monotherapy show that hospitalization cost, which represents the 
driving treatment cost, drops from 74.1% to 67.3% (A) and from 64.5% to 31.6% 
(B) of the total cost; differently maintenance therapy cost increases but it is 
more than offset by the savings accruing from the shortening of hospitalization. 
Furthermore, cost-effectiveness results reveal a mean saving of 216 € (A) and 
900 € (B) other than a mean gain of 0.07 QALY(A) and 0.03 QALY(B). Dominance 
of tiotropium calculated only with patients completing treatment course reveal 
that in almost 30% (A) and 37% (B) of subjects tiotropium strategy is dominant 
while only in 2% (A) and 7% (B) of cases are associated to costs increment and 
worsening on quality of life. cOnclusiOns: These results suggest that adop-
tion of tiotropium as unique treatment in selected mild-to-moderate and severe 
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11 other countries had been included. COPD patients were recorded from a ter-
ritary care hospital in 2012. One-year costs were identified by applying cost data 
to medical information obtained by medical records. The cost analysis was based 
on cost of illness methodology. Costs included those for medications, laboratory 
and diagnostic tests, outpatient visits and hospital stays. Results: There were 612 
patients recruited. Patients were categorized by GOLD classification: 14.29% GOLDI, 
15.28% GOLDII, 38.21% GOLDIII, 32.23% GOLD IV. The median of hospitalization day 
was 9 days. 36.1% of patients were rehospitalized in 90 days. The mortality rate was 
3.1% because of exacerbation. The mean total direct costs was € 4,135.60 per patient 
in a year. The total annual cost was correlated with disease severity. Hospitalization 
contributed the major portion of cost and also correlated with disease severity. 
The average outpatient cost was € 98.62, hospitalization cost including interven-
tion was € 1,548.56, laboratory and diagnostic tests cost were € 103,03, comorbid-
ity and complication cost were € 1.493,88, medication cost with side effects were 
€ 903,59. cOnclusiOns: There is a significant correlation between the cost of COPD 
and disease severity with hospitalization leading to disease exacerbation being a 
major contributor to cost. The keys to reducing health care costs lie beneath reducing 
the frequency of exacerbations and disease severity. As expected, the highest cost 
component was hospitalization, comorbidity and complication cost respectively.
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Objectives: Ireland currently administers a universal BCG vaccination programme 
to infants. In order to assess the cost effectiveness of this programme, it is vital to 
have accurate cost estimates of the burden of tuberculosis (TB) illness in infants. The 
aim of the current study was to cost the diagnosis and treatment of an episode of the 
following health states; pulmonary TB, extrapulmonary TB, TB meningitis and latent 
TB, from the health care payer’s perspective. The cost of contact tracing per primary 
case of TB was also estimated. MethOds: Decision trees were constructed to reflect 
typical episodes of care in the diagnosis and treatment of each health state. Resource 
use and unit cost data were applied to each node in the decision tree. The probabili-
ties of events occurring were derived from the literature and expert clinical opinion. 
Main costs included were inpatient medical/surgical costs, pediatrician outpatient 
appointments, medications, laboratory tests and x-rays. Each health state included a 
cost for a Directly Observed Therapy programme. Direct medical costs were calculated 
and the 2012 price year was used. Results: The direct medical costs of diagnosing 
and treating a case of pulmonary TB, extrapulmonary TB, TB meningitis and latent TB 
were estimated to be approximately € 8153, € 12224, € 15752 and € 894 respectively. The 
main drivers in the costs are the length of hospital stay and the number of pediatri-
cian visits. The cost of contact tracing per primary case of TB was estimated to be 
approximately € 4,248, which was based on a mean number of 9.4 contacts examined 
per primary TB case. cOnclusiOns: To our knowledge this is the first investigation 
of costs associated with paediatric TB within the context of the Irish health care 
setting and will allow for a more robust estimation of the cost effectiveness of BCG 
vaccination programmes, which will benefit the health care payer.
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Objectives: Comparative pharmacoeconomic assessment of COPD therapy of 
patients in GOLD 2-3 stages in Moscow health care system. MethOds: Retrospective 
analysis of 130 cases during 1 year routine practice of patients with COPD in Moscow 
outpatients departments. Basic therapy strategies were obtaned: 1) monotherapy with 
indacaterol (14 pts. Low # of pts is because of the product was launched less than 
year ago); 2) monotherapy by tiotropium (33 pts), 3) fixed combination LABA + ICS 
(38 pts); 4) tiotropium plus fixed combination of LABA and ICS (45 pts). Cost of illness 
via calculation of direct medical costs on diagnostic, hospitalization, treatment of 
main disease and complications based on Federal Standards of COPD treatment and 
regional tariffs on cervices was estimated. Data on prices on medical products were 
obtained from State Register of medical products and www.aptechka.ru. Results: 
The most expencive strategy is management of group 4 - 86.5 KRUR/pt/year (1 Euro 
- 40 RUR) where 67% are costs on base drugs and 31% are hospitalization expenses. 
Usage of fixed combinations LABA + ICS is comparable with monotherapy by tiotro-
pium, total costs are 47 and 49 KRUR/pt/year accordingly. But if the reason of main part 
of the costs in group 3 is hospitalization due to exacerbation - 69%, for group 2 - 61% 
are expenditures on tiotropium. The most preferable is treatment of group 1 - 32847 
RUR/pt/year, where 55% - part on indacaterol, 42% - hospital treatment, 3% - urgent 
care. cOnclusiOns: In spite of high price, indacaterol is the most economic prefer-
able product for basic COPD treatment of patients in GOLD 2-3 stages
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Objectives: To predict health care costs in asthma using the EQ-5D health-related 
quality-of-life (HRQoL) index score. MethOds: We extracted data from the 2000-
03 Medical Expenditure Panel Survey (MEPS) on adult respondents who had EQ-5D 
index scores. Asthma patients were identified using ICD-9 (= 493) and self-report on 
disease (n= 3,783). To account for non-random selection of positive spending, the 
chronic disease with a greater use of pain medications was RA/OA (44.8% vs 41.2%, 
P< 0.0001). COPD patients had more chronic use of short-acting opioids (24.2% vs. 
15.1%, P< 0.0001) and long-acting opioids (4.4% vs. 1.9%, P< 0.0001). Among COPD 
patients, those with chronic pain had higher mean annual direct cost [$24,261 vs. 
$10,390 (p< 0.0001)] which was largely attributable to increased hospitalizations 
(42.7% vs 25.4%, p< 0.0001). By comparison, the mean total medical cost for the 
matched cohort was $17,681 for those with chronic pain compared to $6,543 for 
individuals without chronic pain (P< 0.0001). Pain-related utilization was approxi-
mately 20% of COPD patients’ annual direct cost. cOnclusiOns: COPD patients 
have increased prevalence of and utilization for chronic pain as compared to all 
other chronic illnesses except RA/OA. Individuals with chronic disease and chronic 
pain have more than double the cost of those without chronic pain, and this differ-
ence is even higher among individuals with COPD.
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Objectives: To describe the direct costs to society of COPD per severity grades 
using the “Echantillon Generaliste de Beneficiaires”(EGB). EGB is a database 
which contains all health care resources used by a random 1/97 permanent sam-
ple of the French population covered by the national health care insurance sys-
tem. MethOds: Several algorithms were developed to identify patients with COPD 
and to distinguish patients between four severity grades (1-4) based on health care 
consumption. These algorithms were based on age, rate and history of hospitaliza-
tions, treatments and tests received by the individuals. Exacerbations as well as their 
severity were identified through both antibiotics/corticosteroids drugs prescribed 
and hospitalizations. Total health care costs were calculated and a case-control 
approach was then used to estimate the cost of COPD. Exacerbations costs were 
calculated through a linear regression analysis including age and gender. Results: 
Based on the 10,715 COPD patients identified in the EGB, its prevalence was esti-
mated to 4.2% of the population beyond 40 years. The mean annual overall direct 
health care cost in this population was estimated to be € 9,382. Annual average costs 
were € 7,628; 10,770, 14,979 and 20,747 for severity grade 1-4 (severity data-base 
defined) respectively. The yearly cost of COPD itself was 5,516€ : 45.5% related to 
hospital care and 20.0% to pharmaceuticals (6.0% to long-acting bronchodilators). 
The average exacerbation cost was € 1,664 (SD: € 86.6). The global economic burden of 
COPD in France was therefore estimated over € 7 billions (4% of the national health 
care expense). cOnclusiOns: Our study provides new solutions to estimate the 
burden of COPD in France using existing national databases. It confirms that COPD 
is associated with significant economic burden and the striking direct relationship 
between the cost of care and severity of the disease.
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Objectives: Chronic Obstructive Pulmonary Disease (COPD) is a highly prevalent 
chronic inflammatory disease. Some COPD patients show a co-diagnosis of asthma 
(COPD-A). This real-life observational study assessed the frequency of exacerbations, 
the use of health care resources and their associated costs in patients with COPD only 
and COPD-A. MethOds: Medical records from 6 Primary Care (PC) and one general 
hospital were reviewed and data from 2011 were collected from COPD and COPD-A 
patients aged 40 year or older who met specific inclusion/exclusion criteria. Main 
study variables were demography, co-morbidities, exacerbations and resources utili-
zation. Results: A total of 1210 COPD and 102 COPD-A, mean age (% male) 71.8 (85.5) 
and 71.2 (65.7) years, respectively, were included. Mean co-morbidity burden was simi-
lar in both groups with 7.9 and 7.8 diseases per patient. Most frequent co-morbidities 
(% in COPD; % in COPD-A) were dyslipidemia (63.0; 60.8) and arterial hypertension 
(59.5; 62.7) whereas the proportion of exacerbations (%) were 35.0 and 42.2, respec-
tively. Mean number of exacerbations per patient per year was 1.2 in COPD and 1.6 in 
COPD-A. The frequency of severe exacerbations (%) requiring hospitalizations was 
0.4 and 0.7, while those requiring oral corticosteroids was 24.4 and 33.0, respectively. 
Mean per patient, per year health care resources costs (Euro) were 2152.2 and 2207.5 
for PC-associated costs, and 1361.6 and 1754.3 for specialist care-associated costs, 
respectively. cOnclusiOns: Exacerbations are frequent complications in COPD and 
COPD-A patients. Both groups show high proportion of co-morbidities and use of 
health care resources which were higher in the COPD-A group. Health care-related 
costs are high and are mainly related to hospitalizations and drug therapy.
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Objectives: COPD has a major burden on Turkey’s health care system. It leads 
to high mortality, morbidity and frequent use of health care resources. This study 
determined the total direct health care costs for the management of COPD patients 
with differing degrees of disease severity. The study also aimed to find the key cost 
drivers in the management of COPD in Turkey. MethOds: The methodology was 
based on a study conducted by European Respiratory Society in which Turkey and 
